Clinical Trial · NCT04857502

99mTc-PSMA-I&S in Patients With Prostate Cancer: An Exploratory Biodistribution Study With Histopathology Validation

Overview

This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

Early Phase 1

Contacts

Maria Contreras (Clinical Research Coordinator)

mmcontreras@mednet.ucla.edu

310-825-7336

ClinicalTrials.gov

NCT04857502

Drug / Compound

Isotope(s):

Target(s):

PSMA

Eligibility

Inclusion

Men who received a 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) for staging or restaging
Men who are scheduled for pelvic LN dissection (PLND)
Men who can provide oral and written informed consent
Men with evidence of lymph nodes (LNs)-positive disease on 68Ga-PSMA-11 PET/CT
Men with PCa (primary or recurrent disease)

Exclusion

Patients who started any PCa treatment between study enrollment and surgery
Technically inaccessible nodal location

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…